Formycon AG Reports Preliminary P-III Trial (MAGELLAN-AMD) Results FYB203, a Proposed Biosimilar to Eylea
Shots:
- The company published positive preliminary efficacy and safety data from the P-III trial (MAGELLAN-AMD) evaluating aflibercept biosimilar (FYB203) vs Eylea
- The study met the primary efficacy EPs & showed biosimilarity b/w 2 products in patients with neovascular wet AMD while no differences in safety or immunogenicity were seen. The 1EPs measure the change in best corrected visual acuity after 8wks. from baseline
- Formycon is now announcing the success of FYB203 emphasizing its leadership in this field, following the approval & market launch of an ophthalmological biosimilar for Lucentis (FYB201, marketed as Ongavia in the UK, Ranivisio in the EU, and Cimerli in the US
Ref: FORMYCON | Image: FORMYCON
Related News:- Formycon Reports P-III (VESPUCCI) Trial Results of FYB202 (biosimilar, ustekinumab) for the Treatment of Psoriasis Vulgaris
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
